Literature DB >> 33393168

Debate: Giving prevention a chance to prove its worth in lowering common mental disorder prevalence: how long will it take?

Johan Ormel1, Michael VonKorff2.   

Abstract

Large increases in treatment of Common Mental Disorders (CMD) have failed to reduce population prevalence and global burden. Preventive strategies are needed to lower CMD prevalence and burden. Giving prevention a real chance to prove its promise will require: (a) full embedment in social institutions; (b) long-term structural funding; (c) targeting major CMD determinants early in life combining population-level and individual-level strategies; and, (d) integrated evaluation of short-term and long-term effects to guide implementation. Targeting life skills and resilience of children and parenting skills of their parents has the potential for long-term benefits for multiple outcomes including well-being, social, economic, and financial domains as well as mental health outcomes. However, the large investments may not occur without compelling proof of effectiveness, but evaluation of effectiveness cannot occur without long-term, structural investments. Overcoming this impasse requires a paradigm shift. Randomized controlled trials of initial efficacy need to be supplemented by evaluation strategies for long-term surveillance of community-based programs that guide implementation while assessing long-term effectiveness.
© 2021 The Authors. Child and Adolescent Mental Health published by John Wiley & Sons Ltd on behalf of Association for Child and Adolescent Mental Health.

Entities:  

Year:  2021        PMID: 33393168     DOI: 10.1111/camh.12445

Source DB:  PubMed          Journal:  Child Adolesc Ment Health        ISSN: 1475-357X            Impact factor:   2.175


  1 in total

1.  Study protocol: the OxWell school survey investigating social, emotional and behavioural factors associated with mental health and well-being.

Authors:  Karen Laura Mansfield; Stephen Puntis; Emma Soneson; Andrea Cipriani; Galit Geulayov; Mina Fazel
Journal:  BMJ Open       Date:  2021-12-08       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.